Juvenescence and the Buck Institute launch BHB Therapeutics
February 4, 2019
Juvenescence and the Buck Institute for Research on Aging announce a new collaboration with the formation of BHB Therapeutics, Ltd, a joint venture. The company will focus on novel approaches to inducing a state of ketosis, which may have protective effects against age-related disease.
“There is substantial evidence to support the hypothesis that ketogenesis plays a role in preventative medicine,” said
BHB Therapeutics is based on research conducted in the labs of Eric Verdin, MD and
“Juvenescence is focused on developing and commercializing products that have strong evidence of providing material benefit to an aging population. We believe that some of the compounds identified by Dr. Verdin and Dr. Newman have unique qualities that could provide real benefit,” said
Commenting on the announcement, Founder and Chairman of Juvenescence and Buck Board Member
ABOUT THE BUCK INSTITUTE FOR RESEARCH ON AGING
Our success will ultimately change healthcare. At the Buck, we aim to end the threat of age-related diseases for this and future generations by bringing together the most capable and passionate scientists from a broad range of disciplines to identify and impede the ways in which we age. An independent, nonprofit institution, our goal is to increase human health span, or the healthy years of life. Globally recognized as the pioneer and leader in efforts to target aging, the number one risk factor for serious diseases including Alzheimer's, Parkinson's, cancer, macular degeneration, heart disease, and diabetes, the Buck wants to help people live better longer. Learn more at: https://buckinstitute.org.
ABOUT JUVENESCENCE LTD.
Juvenescence Limited is a life sciences company developing therapies to modify aging and increase healthy human longevity. It was founded by
Link to the BusinessWire Press release found here.